Company: GNMSF
Filing Date: 2025-02-12
Form Type: 20-F
Source: 0001558370-25-000846
Chunk: 1

Company: GENMAB A/S
Filing Date: 2025-02-12
Form: 20-F
Item: Item 3
Chunk 1
---
ITEM 3 KEY INFORMATION

B. Capitalization and Indebtedness

Not applicable.

C. Reasons for the Offer and Use of Proceeds

Not applicable.

D. Risk Factors

Summary

Our business is subject to numerous risks and uncertainties. You should carefully consider these risks and uncertainties when investing in our ordinary shares or American depositary shares (“ADSs”). The principal risks and uncertainties affecting our business include the following:

Table of Contents

  The substantial majority of our revenue comes from royalties on sales of DARZALEX, and our patents underlying these royalties will start to expire in the late 2020s.  

  The launch of a new product or of an existing product in a new indication or territory is subject to a number of risks and uncertainties and may not be successful.  
 ───────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────

  Our business and operations have experienced rapid growth that needs to be carefully managed.  

  We may acquire businesses or products, form collaborations or enter into other strategic transactions in the future. We may need to raise additional capital to fund these transactions and we ma...  
 ────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────

  Sales of our products will depend on the degree of market acceptance by physicians, patients, healthcare payers and others in the medical community.  

  We rely on our collaboration partners in many aspects of our business.  

  We rely on third parties to conduct clinical trials.  

  We rely on a limited number of third-party manufacturers for our product supply.  

  Biopharmaceutical product development involves a substantial degree of uncertainty.  

  Our product candidates will need to undergo clinical trials that are time-consuming and expensive, the outcomes of which are unpredictable, and for which there is a high risk of failure.  

  Any approval granted for our products or product candidates in the U. S. does not assure approval of such products in Japan and the EU or other foreign jurisdictions.  

  We may be affected by reports of adverse events or safety concerns relating to our products or product candidates.  
 ──────────────────────────────────────────────────────────────────────────────────────────────────────────────────────

  We may face product liability claims related to the use or misuse of our products or technologies.  
 ──────────────────────────────────────────────────────────────────────────────────────────────────────

  Our business applications and information technology